Prelude Therapeutics (PRLD)
NASDAQ: PRLD
· Real-Time Price · USD
0.92
-0.04 (-4.14%)
At close: May 01, 2025, 3:59 PM
0.88
-3.82%
After-hours: May 01, 2025, 06:55 PM EDT
-4.14% (1D)
| Bid | 0.87 |
| Market Cap | 51.72M |
| Revenue (ttm) | 7M |
| Net Income (ttm) | -127.17M |
| EPS (ttm) | -1.68 |
| PE Ratio (ttm) | -0.55 |
| Forward PE | -0.93 |
| Analyst | Buy |
| Ask | 0.98 |
| Volume | 78,238 |
| Avg. Volume (20D) | 202,090 |
| Open | 0.97 |
| Previous Close | 0.96 |
| Day's Range | 0.91 - 0.99 |
| 52-Week Range | 0.61 - 6.80 |
| Beta | 1.34 |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selecti...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 131
Stock Exchange NASDAQ
Ticker Symbol PRLD
Website https://www.preludetx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 336.59% from the latest price.
Stock Forecasts